In-hospital empagliflozin initiation yielded similar clinical benefits in both de novo and acute decompensated chronic heart failure patients despite reduced diuretic response in ADHF.
Does in-hospital initiation of empagliflozin provide similar clinical benefits in de novo heart failure versus acute decompensated chronic heart failure?
In-hospital initiation of empagliflozin is well tolerated and provides clinical benefits across both de novo and acute decompensated chronic heart failure presentations.
In-hospital initiation of empagliflozin produced similar clinical benefits in NHF and ADHF despite the reduced diuretic response in participants with ADHF and was well tolerated. This supports in-hospital initiation of empagliflozin in all patients with acute HF (A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure EMPULSE; NCT04157751).
Angermann et al. (2026) studied this question. In-hospital empagliflozin initiation yielded similar clinical benefits in both de novo and acute decompensated chronic heart failure patients despite reduced diuretic response in ADHF.